Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome

Nutrition

Volumn 32, Issue 6, 2016, Pages 716-719

  Bernini, Luciana Jesus ^a   Simão, Andrea Name Colado ^b   Alfieri, Daniela Frizon ^b   Lozovoy, Marcell Alysson Batisti ^b   Mari, Naiara Lourenço ^b   de Souza, Cínthia Hoch Batista ^a   Dichi, Isaías ^b   Costa, Giselle Nobre ^a  

^a UNIVERSIDADE NORTE DO PARANÁ   (Brazil)

^b University Hospital of Londrina   (Brazil)

Author keywords

Bifidobacterium lactis; Cardiovascular risk factors; Cytokines; Metabolic syndrome; Probiotic

Indexed keywords

CHOLESTEROL; CYTOKINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIUM IDENTIFICATION; BIFIDOBACTERIUM ANIMALIS; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIET SUPPLEMENTATION; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MILK; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT RESPONSE; ADOLESCENT; ADULT; BIFIDOBACTERIUM; BLOOD; DIET THERAPY; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; BIFIDOBACTERIUM; CYTOKINES; FEMALE; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROBIOTICS; YOUNG ADULT;

EID: 84964794736     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2015.11.001     Document Type: Article

References (23)

1. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112:2735-2752.
2. Ley R.E., Bäckhed F., Turnbaugh P., Lozupone C.A., Knight R.D., Gordon J.I. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005, 102:11070-11075.
3. Guarner F., Malangelada J.R. Gut flora in health and disease. Lancet 2003, 361:512-519.
4. Sanz Y., Santacruz A., Dalmau J. Influencia de la microbiota intestinal em la obesidad y las alteraciones del metabolismo. Acta Pediatr Esp 2009, 67:437-442.
5. Santacruz A., Collado M.C., García-Valdés L., Segura M.T., Martín-Lagos J.A., Anjos T., et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr 2010, 104:83-92.
6. Million M., Lagier J.C., Yahav D., Paul M. Gut bacterial microbiota and obesity. Clin Microbiol Infect 2013, 19:305-313.
7. Borriello S.P., Hammes W.P., Holzapfel W., Marteau P., Schrezenmeir J., Vaara M., et al. Safety of probiotics that contain Lactobacilli or Bifidobacteria. Clin Infect Dis 2003, 36:775-780.
8. Ashraf R., Shah N.P. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr 2014, 54:938-956.
9. Miglioranza Scavuzzi B., Miglioranza L.H., Henrique F.C., Pitelli Paroschi T., Lozovoy M.A., Simão A.N., et al. Role of probiotics on each component of the metabolic syndrome and other cardiovascular risks. Expert Opin Ther Targets 2015, 19:1127-1138.
10. Resolução RDC n°. 12, de 2 de janeiro de 2001. Regulamento técnico sobre padrões microbiológicos para alimentos 2001, BRASIL, Diário Oficial da União, Brasília, DF, Available at:, Accessed March 14, 2015. http://www.anvisa.gov.br/legis/resol/12_01rdc.htm.
11. Haffner S.M. Insulin resistance, inflammation and the prediabetic state. Am J Cardiol 2003, 92:18J-26J.
12. Barreto F.M., Simão A.N., Morimoto H.K., Lozovoy M.A.B., Dichi I., Miglioranza L.H.S. Beneficial effects of Lactobacillus plantarum on glycemia and homocysteine levels in postmenopausal women with metabolic syndrome. Nutrition 2014, 30:939-942.
13. Isolauri E., Salminen S., Ouwehand A.C. Probiotics. Best Pract Res Clin Gastroenterol 2004, 18:299-313.
14. Diamant M., Blaak E.E., de Vos W.M. Do nutrient gut microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?. Obes Rev 2011, 12:272-281.
15. Guo Z., Liu X.M., Zhang Q.X., Shen Z., Tian F.W., Zhang H., et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis 2011, 21:844-850.
16. Brashears M.M., Gilliland E., Buck L.M. Bile salt deconjugation and cholesterol removal from media by Lactobacillus casei. J Dairy Sci 1998, 81:2103-2110.
17. Greany K.A., Bonorden M.J., Hamilton-Reeves J.M., McMullen M.H., Wangen K.E., Phipps W.R., et al. Probiotic capsules do not lower plasma lipids in young women and men. Eur J Clin Nutr 2008, 62:232-237.
18. Begley M., Hill C., Gahan C.G. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 2006, 72:1729-1738.
19. Zhuang G., Liu X.-M., Zhang Q.-X., Tian F.-W., Zhang H., Zhang H.-E., et al. Research advances with regards to clinical outcome and potential mechanisms of the cholesterol-lowering effects of probiotics. Clin Lipidology 2012, 7:501-507.
20. Asemi Z., Zare Z., Shakeri H., Sabihi S.S., Esmaillzadeh A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab 2013, 63:1-9.
21. Gøbel R.J., Larsen N., Jakobsen M., Mølgaard C., Michaelsen K.F. Probiotics to adolescents with obesity: Effects on inflammation and metabolic syndrome. J Pediatr Gastroenterol Nutr 2012, 55:673-678.
22. Andreasen A.S., Larsen N., Pedersen-Skovsgaard T., Berg R.M., Møller K., Svendsen K.D., et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr 2010, 104:1831-1838.
23. Kelly C.J., Colgan S., Frank D.N. Of microbes and meals: the health consequences of dietary endotoxemia. Nutr Clin Pract 2012, 27:215-225.